ISC Releases Investor Presentation Highlighting A Proven Model for Value Creation
ISC reaffirms its commitment to long-term shareholder value creation and disciplined capital allocation; responds to Plantro's incorrect and flawed assertions
Analysis demonstrates that ISC's prudent and disciplined approach to growth and capital allocation has served all shareholders well, outperforming the S&P TSX Small Cap Index since the IPO in July 2013
ISC remains focused on performance, not provocation
REGINA, Saskatchewan, May 12, 2025 (GLOBE NEWSWIRE) -- Information Services Corporation (TSX: ISC) ('ISC' or the 'Company') today released an investor presentation titled 'A Proven Model for Value Creation', which underscores the strength, stability and strategic vision that have defined ISC's track record over more than a decade. The presentation is available here on the Company's website.
ISC has evolved into a diversified business with global scale, including a high-quality registry platform and a services segment delivering consistent, accretive growth. The Company's registry operations remain anchored by a long-term exclusive contract in Saskatchewan until 2053, providing stable, CPI-linked cash flows for nearly 30 years. The Company's disciplined M&A strategy has been supported entirely through balance sheet capacity.
Since its IPO, ISC has:
Significantly diversified its operations, which has led to nearly tripling its revenue and Adjusted EPS
Executed against a proven and accretive M&A strategy that has delivered nearly $100 million in free cash flow generated by the Services segment since 2015
Achieved revenue compound annual growth rate ('CAGR') growth of ~13.6 per cent since 2015
Provided a clear roadmap for continuing growth
Delivered a total shareholder return ('TSR') of 209 per cent, outperforming the S&P/TSX SmallCap Index since the IPO in July 2013
The Company remains committed to advancing a strategy grounded in stability, disciplined capital allocation and long-term shareholder value creation. To that end, ISC has released an investor presentation, available here on the Company's website.
ISC remains focused on performance, not provocation. The Company is resilient and diversified, with an experienced board and leadership team committed to executing a value-driven plan. ISC will continue to act in the best interests of all shareholders.
PLANTRO'S CAMPAIGN OF MISINFORMATION AND COERCION
ISC believes that offshore entity Plantro Ltd.'s ('Plantro') repeated extensions to its unsolicited and undervalued Mini-tender offer (the 'Mini-tender') are a reflection of broad shareholder disinterest in the Mini-tender. ISC continues to recommend that shareholders Reject and Do Not Tender to Plantro's undervalued Mini-Tender.
The Company also fundamentally disagrees with Plantro's assessment of the Company's strategy, governance and value creation. Plantro's presentation contains factual errors, several points and data that are selective and narrowly focused on building a particular narrative, and others that demonstrate a lack of understanding of the business, including ISC's approach to M&A and its compensation and incentive programs. In light of continued mischaracterizations by Plantro, ISC urges shareholders to access accurate information through ISC's public disclosure and filings available on ISC's website at company.isc.ca and under ISC's profile on SEDAR+ at www.sedarplus.ca.
It is unfortunate that Plantro has pursued a path that undermined engagement from the outset. ISC is and has always demonstrated genuine interest in having constructive conversations with its shareholders and other stakeholders. Notwithstanding that Plantro did not engage at all with ISC, constructively or otherwise, ahead of its Mini-tender, the Company attempted to engage in good-faith dialogue with Plantro.
ISC APPRECIATES BROAD SHAREHOLDER SUPPORT AMID DISTRACTIONS
The Company wants to acknowledge and thank its many shareholders for their continued support; it is not something that is taken for granted. ISC has had, and continues to have, meaningful dialogue with all stakeholders as we look forward to the future success of the Company. Sifting through the noise and the distractions and being attentive to constructive and impactful suggestions will continue to improve the business and the returns to shareholders.
Finally, and further to our focus on performance, the Company does not intend to continue a public dispute with either Plantro or Matthew Proud, unless it determines that disclosure is warranted due to further misinformation by Plantro or in accordance with the requirements of applicable securities law. Instead, and as always, ISC remains committed and prepared to engage with shareholders and interested investors who wish to have constructive and good faith dialogue with us.
AdvisorsISC has engaged Kingsdale Advisors as its strategic shareholder and communications advisor, Stikeman Elliott LLP as legal advisor, and RBC Capital Markets as financial advisor.
About ISC®Headquartered in Canada, ISC is a leading provider of registry and information management services for public data and records. Throughout our history, we have delivered value to our clients by providing solutions to manage, secure and administer information through our Registry Operations, Services and Technology Solutions segments. ISC is focused on sustaining its core business while pursuing new growth opportunities. The Class A Shares of ISC trade on the Toronto Stock Exchange under the symbol ISC.
Cautionary Note Regarding Forward-Looking InformationThis news release contains forward-looking information within the meaning of applicable Canadian securities laws including, without limitation, statements related to ISC's continuing growth, its strategy, its focus on performance, its commitment to executing a value-driven plan, acting in the best interests of shareholders, its interest in constructive conversations with stakeholders and its intentions in relation to Plantro Ltd. or Matthew Proud.
Investor ContactJonathan HackshawSenior Director, Investor Relations & Capital MarketsToll Free: 1-855-341-8363 in North America or 1-306-798-1137investor.relations@isc.ca
Media ContactAquin GeorgeKingsdale Advisors1-416-644-4031ageorge@kingsdaleadvisors.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Rachel Reeves only has herself to blame for this recession
Companies were hammered by a steep rise in employment taxes. Business rates went up sharply as reliefs were wound down. The living wage was pushed up, and stamp duty breaks were slashed. Against that dismal backdrop, it is probably a miracle that the GDP figures for April published today recorded only a 0.3 per cent month-on-month decline in output. The Chancellor Rachel Reeves will shamelessly try to blame that on the tariff war started by president Trump. But the blunt truth is this. The unfolding recession was entirely predictable – and she has only herself to blame. April was always going to be a tough month for anyone struggling to run a business in the UK. Employer National Insurance went up, and we saw the initial impact of that in the annual loss of 274,000 jobs in the employment data reported earlier this week. Likewise, one of the biggest rises in the living wage was imposed, and we saw the effect of that in declining hours worked in sectors such as shops and restaurants, which need lots of modestly paid staff. Business rates went up sharply, as reliefs were wound down, with many pubs facing an extra £12,000 or more in the amount that they have to pay to the local council, and closures are now running at 100 a month. Stamp duty went up as reliefs were phased out, and we have already seen the consequences of that in the 0.4 per cent decline in home prices reported by Halifax last week. In the background, industrial electricity prices have remained by far the highest in the world, forcing factories to close their doors. One by one Reeves has taken the major sectors of the British economy – property, hospitality, retailing and manufacturing – and whacked them with huge extra charges. Sure, it didn't help that the US imposed tariffs on the UK along with its other major trading partners. And yet, in reality, the sharp fall in output witnessed in April was entirely self-imposed. It took an extraordinary level of incompetence, and a breath-taking level of arrogance, to sequence such a punishing round of tax increases so that they all kicked in at the same time. It is not as if Reeves was not warned of the devastating impact of her tax rises on businesses. The M&S boss Stuart Machin called for the NI rise to be phased in back in February but was ignored. The British Beer and Pub Association called for help with business rates, but no one at the Treasury paid any attention. Rightmove called for stamp duty relief to be extended, and so did many other estate agents, but the Government didn't listen. The list goes on and on. Time and time again, businesses have told the Chancellor that her policies are killing their trade, only to be ignored. As it has turned out, however, they were completely right, and today's GDP figures have proved that. It is going to get much worse over the next few months. We have only seen the start of the fall in employment after the NI rise. After all, if your wage bill is out of control, it takes time to slim staff numbers. There are procedures to follow before you dismiss someone, and most small companies will rely on natural wastage, and simply not replace people, instead of risking the cost of an employment tribunal. Stamp duty has only just gone up, and it will take buyers a while to figure out they can no longer afford to move. Meanwhile, retail sales are falling again, and the inevitability of more tax rises on business in the autumn is deterring investment. Reeves chose to ignore the warnings that her tax raids would crash the economy. She will now have to reap the consequences of those decisions – and unfortunately so will the rest of us. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Yahoo
an hour ago
- Yahoo
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next key milestone in the execution of its oncology strategy Acquisition of CureVac will complement BioNTech's capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing Public exchange offer for all shares of CureVac where each share of CureVac will be exchanged for approx. $5.46 in BioNTech American Depositary Shares ('ADSs'), representing a premium of 55% to CureVac's three-month volume weighted average price of approx. $3.53 as of June 11, 2025 All-stock acquisition has potential to create long-term value for both companies' shareholders given their complementary capabilities, focus on mRNA innovation, and shared vision Transaction is supported by CureVac's major shareholder dievini Hopp BioTech holding GmbH & Co. KG and certain of its affiliates and expected to close in 2025 MAINZ and TÜBINGEN, Germany, June 12, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, 'BioNTech') and CureVac N.V. (Nasdaq: CVAC, 'CureVac') today announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a clinical-stage biotech company developing a novel class of transformative medicines in oncology and infectious diseases based on messenger ribonucleic acid ('mRNA'). The all-stock transaction will bring together two highly complementary companies based in Germany and will build on BioNTech's proven track record and established position in the global mRNA industry. With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialization of investigational mRNA-based cancer immunotherapy. The strategic transaction will complement BioNTech's capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing. For BioNTech, this transaction marks the next milestone in the execution of its oncology strategy which focuses on two pan-tumor programs, mRNA-based cancer immunotherapy candidates, and BNT327, a PD-L1xVEGF-A bispecific antibody candidate. Under the terms of the Purchase Agreement, each CureVac share will be exchanged for approx. $5.46 in BioNTech ADSs, resulting in an implied aggregate equity value for CureVac of approx. $1.25 billion (subject to the adjustments described below). The consideration is subject to a collar mechanism, such that if the 10-day volume weighted average price of the BioNTech ADSs ending on the fifth business day prior to the closing of the offer ('VWAP') exceeds $126.55, the exchange ratio would be 0.04318, and if the VWAP is lower than $84.37, the exchange ratio would be 0.06476. Upon closing of the transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech. 'This transaction is another building block in BioNTech's oncology strategy and an investment in the future of cancer medicine,' said Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. 'We intend to bring together complementary capabilities and leverage technologies with the goal of advancing the development of innovative and transformative cancer treatments and establishing new standards of care for various types of cancer in the coming years.' 'To me, this transaction is more than a business decision, it represents a shared commitment to leverage the full potential of mRNA as a disruptive technology to develop transformative therapies with greater scale and speed,' said Dr. Alexander Zehnder, CEO of CureVac. 'For more than two decades, both companies have operated with related ambitions, often tackling challenges from different angles. This transaction aims at combining complementary scientific capabilities, proprietary technologies, and manufacturing expertise in the mRNA field under one roof.' BioNTech will start preparing an integration plan in alignment with BioNTech's ongoing group-wide transformation. Following the closing of the transaction, CureVac's operating subsidiary will become a wholly owned subsidiary of BioNTech. As part of this plan, BioNTech will integrate CureVac's state-of-the-art research and manufacturing site in Tübingen. BioNTech's all-stock acquisition of CureVac is expected to create long-term value for shareholders of both companies, building on BioNTech's proven track record in mRNA research, development, manufacturing, and commercialization, in particular the COVID-19 vaccine, which was developed in collaboration with Pfizer Inc. and marked the first approved mRNA product in the history of medicine. Based on BioNTech's strong financial position with €15.9 billion in cash, cash equivalents and security investments as of March 31, 2025, its global presence, late-stage clinical pipeline, and sustained investment in mRNA research across a broad range of solid tumor types, the acquisition positions the company to accelerate and broaden the development of mRNA-based medicines for patients in need. Following the closing of the exchange offer BioNTech and CureVac will effectuate a corporate reorganization of CureVac and its subsidiaries, resulting in BioNTech owning 100% of CureVac's business and interests in CureVac and its subsidiaries. As part of this corporate reorganization, CureVac shareholders who do not tender their shares in the exchange offer will receive the same consideration received for each CureVac share tendered in the exchange offer (without interest and subject to applicable withholding taxes). An extraordinary general meeting of CureVac's shareholders will be convened in connection with the exchange offer to adopt, among other things, certain resolutions relating to the transaction. The transaction was unanimously approved by both BioNTech's and CureVac's management and supervisory boards. The transaction, which is expected to close in 2025, is subject to the satisfaction of customary closing conditions, including a minimum acceptance threshold of at least 80% of CureVac's shares (which threshold may be reduced to 75% unilaterally by BioNTech under certain circumstances) and required regulatory approvals. Certain shareholders of CureVac representing 36.76% of CureVac's shares, including dievini Hopp BioTech holding GmbH & Co. KG and certain of its affiliates and all members of CureVac's management and supervisory boards, have entered into tender and support agreements, pursuant to which they have agreed, among other things, and subject to the terms and conditions of such agreements, to tender their shares in the exchange offer and to vote in favor of the resolutions relating to the transaction at the CureVac extraordinary general meeting to be held in connection with the transaction. In addition, the German Federal government has confirmed to generally have a positive view on the transaction. BioNTech therefore assumes that Kreditanstalt für Wiederaufbau – which holds 13.32% of the shares in CureVac on behalf of the Federal Republic of Germany – will support the transaction by tendering its shares in CureVac. As a result, BioNTech expects to have contractual commitments to support the transaction from shareholders of CureVac representing a total of 50.08% of CureVac shares towards the 80% minimum condition required under the exchange offer. Covington & Burling LLP, Hengeler Mueller Partnerschaft von Rechtsanwälten mbB and Loyens & Loeff N.V. served as legal counsel to BioNTech. Skadden, Arps, Slate, Meagher & Flom LLP and NautaDutilh N.V. served as legal counsel to CureVac. PJT Partners served as exclusive financial advisor to BioNTech. Goldman Sachs Bank Europe SE served as exclusive financial advisor to CureVac. About BioNTechBiopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and more information, please visit About CureVacCureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. CureVac's mRNA platform incorporates a series of novel technologies, designed to improve the efficacy, safety and cost-effectiveness of mRNA therapeutics aimed at resulting in enhanced immune responses at lower doses. Additionally, CureVac has developed LNPs, which have been optimized for indication specific use across infectious diseases and oncology. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. It also develops programs in prophylactic vaccines and in treatments that aim to enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at Cautionary Statement Regarding Forward-Looking Statements This document includes 'forward-looking statements,' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'plan,' 'may,' 'could,' 'would,' 'expect,' 'look forward,' 'investigational,' 'pipeline,' 'to acquire,' 'development,' 'to include,' 'commitment,' or similar terms. Such forward-looking statements include, but are not limited to, statements relating to the ability of BioNTech and CureVac to complete the transactions contemplated by the Purchase Agreement (including the parties' ability to satisfy the conditions to the consummation of the exchange offer contemplated thereby and the other conditions set forth in the Purchase Agreement), the expected timetable for completing the transactions, the benefits sought to be achieved in the proposed transactions, the potential and capacity of BioNTech following the transaction and the potential effects of the proposed transactions on BioNTech and CureVac. Many of these risks and uncertainties are beyond the control of BioNTech or CureVac. Investors are cautioned that any such forward-looking statements are based on BioNTech's or CureVac's current beliefs and expectations regarding future events and are not guarantees of future performance and involve risks and uncertainties. There can be no guarantees that the conditions to the closing of the transactions will be satisfied on the expected timetable or at all. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements. Risks and uncertainties include, but are not limited to, uncertainties as to the timing of the exchange offer and the subsequent corporate reorganization of CureVac; uncertainties as to how many of CureVac's shareholders will tender their shares in the exchange offer; the risk that competing offers or acquisition proposals will be made; the possibility that various conditions to the consummation of the exchange offer and the transactions contemplated by the Purchase Agreement may not be satisfied or waived; the possibility of a termination of the Purchase Agreement; the ability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing; the effects of disruption from the transactions contemplated by the Purchase Agreement and the impact of the announcement and pendency of the transactions on BioNTech's and/or CureVac's business, including their relationships with employees, business partners or governmental entities; the risk that the exchange offer or the other transactions contemplated by the Purchase Agreement may be more expensive to complete than anticipated; the risk that litigation in connection with the exchange offer or the other transactions contemplated by the Purchase Agreement may result in significant costs of defense, indemnification and liability; a diversion of management's attention from ongoing business operations and opportunities as a result of the exchange offer, the other transactions contemplated by the Purchase Agreement or otherwise; general industry conditions and competition; general political, economic and business conditions, including interest rate, inflation, tariff and currency exchange rate fluctuations, and the ongoing Russia-Ukraine and Middle East conflicts; the impact of regulatory developments and changes in the United States, Europe and countries outside of Europe, including with respect to tax matters; the impact of pharmaceutical industry regulation and health care legislation in the United States, Europe and elsewhere; the particular prescribing preferences of physicians and patients; competition from other products; challenges and uncertainties inherent in new product development; ability to obtain or maintain proprietary intellectual property protection; safety, quality, data integrity or manufacturing issues; and potential or actual data security and data privacy breaches. Neither BioNTech nor CureVac undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in BioNTech's and CureVac's respective Annual Report on Form 20-F for the year ended December 31, 2024, in each case as amended by any subsequent filings made with the U.S. Securities and Exchange Commission (the 'SEC'), available on the SEC's website at Notice to Investors and Security HoldersThis document is for information purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the proposed transactions, BioNTech intends to file a Registration Statement on Form F-4 (the 'Registration Statement') with the U.S. Securities and Exchange Commission (the 'SEC'), including an offer to exchange/prospectus to register, under the Securities Act of 1933, as amended, the issuance of BioNTech's American Depositary Shares ('ADSs') pursuant to the exchange offer. In addition, BioNTech intends to file a Tender Offer Statement on Schedule TO (the 'Schedule TO'), which will include, as exhibits, the offer to exchange/prospectus, a form of letter of transmittal and other customary ancillary documents, with the SEC and soon thereafter CureVac intends to file a Solicitation/Recommendation Statement on Schedule 14D-9 (the 'Schedule 14D-9') with respect to the exchange offer. The exchange offer for the common shares of CureVac referred to in this document has not yet commenced. The solicitation and offer to purchase CureVac's common shares will only be made pursuant to the Schedule TO and related exchange offer/prospectus. This material is not a substitute for the offer to exchange/prospectus, the Schedule TO, the Schedule 14D-9, the Registration Statement or for any other document that BioNTech or CureVac may file with the SEC and send to CureVac's shareholders in connection with the proposed transactions. With respect to the public offering of BioNTech ADSs to CureVac shareholders in Germany and in any other member state of the European Economic Area, this document is an advertisement for the purposes of the prospectus regulation EU 2017/1129, as amended. It does not constitute an offer to purchase any BioNTech ADSs or shares in BioNTech and does not replace the securities prospectus which will be available free of charge, together with the relevant translation(s) of the summary, from BioNTech's website ( The approval of the securities prospectus by the German Federal Financial Supervisory Authority should not be understood as an endorsement of the investment in any BioNTech ADSs or shares in BioNTech. Investors in Germany and in any other member state of the European Economic Area should acquire BioNTech ADSs solely on the basis of the prospectus (including any supplements thereto, if any) relating to the ADSs and should read the prospectus which is yet to be published (including any supplements thereto, if any) before making an investment decision in order to fully understand the potential risks and rewards associated with the decision to invest in the BioNTech ADSs. Investment in BioNTech ADSs entails numerous risks, including a total loss of the initial investment. With respect to the public offering of BioNTech ADSs to CureVac shareholders in the United Kingdom (the 'UK'), BioNTech will publish a UK prospectus exemption document for the purposes of the prospectus regulation EU 2017/1129 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended. This document does not constitute an offer to purchase any BioNTech ADSs or shares in BioNTech and does not replace the UK prospectus exemption document which will be available free of charge from BioNTech's website ( Investors in the UK should acquire BioNTech ADSs solely on the basis of the UK prospectus exemption document (including any supplements thereto, if any) relating to the BioNTech's ADSs and should read the UK prospectus exemption document which is yet to be published (including any supplements thereto, if any) before making an investment decision in order to fully understand the potential risks and rewards associated with the decision to invest in the BioNTech ADSs. Investment in BioNTech ADSs entails numerous risks, including a total loss of the initial investment. BEFORE MAKING ANY INVESTMENT DECISION OR DECISION WITH RESPECT TO THE EXCHANGE OFFER, WE URGE INVESTORS OF CUREVAC TO READ THE REGISTRATION STATEMENT, EXCHANGE OFFER/PROSPECTUS, SCHEDULE TO (INCLUDING THE EXCHANGE OFFER, RELATED LETTER OF TRANSMITTAL AND OTHER OFFER DOCUMENTS) AND SCHEDULE 14D-9, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND OTHER RELEVANT DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT BIONTECH, CUREVAC AND THE PROPOSED TRANSACTIONS THAT HOLDERS SHOULD CONSIDER. Investors will be able to obtain free copies of the Registration Statement, exchange offer/prospectus, Schedule TO and Schedule 14D-9, as each may be amended from time to time, and other relevant documents filed by BioNTech and CureVac with the SEC (when they become available) at the SEC's website, or free of charge from BioNTech's website ( or by contacting BioNTech's Investor Relations Department at investors@ These documents are also available free of charge from CureVac's website ( or by contacting CureVac's Investor Relations Department at communications@ CONTACTS BioNTech: Investor RelationsDouglas Maffei, PhDInvestors@ Media RelationsJasmina AlatovicMedia@ CureVac: Media and Investor Relationscommunications@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
USA Today
an hour ago
- USA Today
Texas A&M transfer WR signs NIL deal with trading card company
Texas A&M transfer WR signs NIL deal with trading card company Texas A&M's 2025 wide receiver rotation is completely revamped after the additions of KC Concepcion (NC State), Jonah Wilson (Houston), and Mario Craver (Mississippi State) this offseason, while the return of Terry Bussey, Ashton Bethel-Roman and Izaiah Williams has given starting quarterback Marcel Reed an elite corps that should take the Aggie passing game to the next level. With elite talent comes NIL earnings, and after the NCAA vs. House bill was passed, Universities will now directly pay their athletes with a $20.5 million cap per institution. At the same time, players will continue to be able to sign NIL deals with various organizations. This week, it was revealed that KC Concepcion signed a $2.5 million deal with The Famile. In contrast, Jaxson Callaway of AggiesToday revealed on Wednesday that Marion Craver has reportedly signed his NIL deal with Topps Trading Cards. According to Callaway, Craver will work with a variety of trading cards ranging from Autograph, Relic, Chrome, and Specialty Sets. As Callaway notes in the article, Craver's ascending profile and star potential after his freshman season with the Bulldogs are the primary reasons Topps is so excited about his representation moving forward. "Mario Craver is as an emerging figure in the trading card market, leveraging his collegiate status to contribute to Topps' diverse portfolio. The inclusion of autographs and jerseys taps into the growing demand for authenticated memorabilia, especially as Topps expands with 2025 releases like Series 2 and Chrome. Collectors can anticipate Craver's cards in hobby boxes or as standalone rarities, available through Topps' official site or retailers like Target, with potential value increases if his career progresses." Craver enters the 2025 season as the No. 2 or 3 option, depending on the results of fall practices, providing Marcel Reed with a legitimate deep threat who can take the top of most secondaries. His quickness in route will create immediate separation in the short passing game. Contact/Follow us @AggiesWire on X (formerly Twitter) and like our page on Facebook to follow ongoing coverage of Texas A&M news, notes and opinions. Follow Cameron on X: @CameronOhnysty.
